MIP-1alpha, human recombinant

(No reviews yet) Write a Review
SKU:
4244-20
$183
Frequently bought together:

Description

MIP-1alpha, human recombinant is available at Gentaur for Next week delivery.

Recruits and activates polymorphonuclear leukocytes

Biomolecule/Target: MIP-1 alpha

Alternates names: Small inducible cytokine A3, CCL3, Macrophage inflammatory protein 1-α, MIP-1-α, Tonsillar lymphocyte LD78 α protein, G0/G1 switch regulatory protein 19-1, G0S19-1 protein, SIS-β, PAT 464,1, chemokine (C-C motif) ligand 3, MIP1A, SCYA3, G0S19-1, LD78α, TY-5, SIS-α, Heparin-binding chemotaxis protein, L2G25B,

Synonyms: Small inducible cytokine A3, CCL3, Macrophage inflammatory protein 1-α, MIP-1-α, Tonsillar lymphocyte LD78 α protein, G0/G1 switch regulatory protein 19-1, G0S19-1 protein, SIS-β, PAT 464,1, chemokine (C-C motif) ligand 3, MIP1A, SCYA3, G0S19-1, LD78α, TY-5, SIS-α, Heparin-binding chemotaxis protein, L2G25B,

Background Information: Human microphage inflammatory protein-1 α (MIP-1α is a 7.8 kDa protein containing 70 amino acid residues. It plays an important role in the inflammatory response of blood monocytes and tissue microphages.

Reconstitution Instructions: Reconstitute in H₂O to a concentration of 0.1-1.0 mg/ml. The solution can be diluted into other aqueous buffers

NCBI Gene Symbol: CCL3

Gene ID: 6348

NCBI Accession: P10147

View AllClose

Additional Information

Size:
20 μg
Adwords:
Yes
Country of Manufacturing Origin:
USA
Country of Animal Origin:
USA
Gene Source:
Human
Recombinant:
Yes
Source:
E. coli
Purity by SDS-PAGE:
≥98%
Assay:
SDS-PAGE
Purity:
≥98%
Assay 2:
HPLC
Endotoxin Level:
<0.1 ng/μg
Activity (Specifications/test method):
N/A
Biological activity:
Activity was determined by its ability to chemoattract human monocytes using a concentration range of 1.0-10 ng/ml.
Results:
1.0-10 ng/ml.
Molecular Weight:
7.8 kDa
Storage Temperature:
-20°C
Shelf Life:
12 months
Concentration:
N/A
Appearance:
Lyophilized protein
Handling:
Centrifuge the vial prior to opening.
View AllClose

0 Reviews

View AllClose